Clinical Trials Logo
  1. Home
  2. Liposarcoma
  3. NCT02343172

Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With Liposarcoma

Liposarcoma Clinical Trial

Official title:
A Phase Ib/II, Open-label, Multicenter Study of Oral HDM201 in Combination With Oral LEE011 in Adult Patients With Liposarcoma

Clinical Trial Summary

To determine the MTD/RP2D of the HDM201 and LEE011 combination and evaluate whether the combination is safe and has beneficial effects in patients with liposarcoma.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02343172
Study type Interventional
Source Novartis
Contact
Status Completed
Phase Phase 1
Start date March 13, 2015
Completion date October 16, 2019
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Recruiting NCT04557449 - Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors Phase 1/Phase 2
Completed NCT01209598 - PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma Phase 2
Withdrawn NCT04906876 - A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas Phase 2
Not yet recruiting NCT06039046 - Investigating Engagement Patterns and Participation Trends Among Liposarcoma Patients
Recruiting NCT02983539 - Detection of Circulating Tumor Cells in Patients With Sarcomas
Completed NCT02249949 - Efatutazone Dihydrochloride in Treating Patients With Previously Treated Myxoid Liposarcoma That Cannot Be Removed by Surgery Phase 2
Completed NCT00093080 - Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED) Phase 2
Completed NCT03303885 - The FGF/FGFR Signalling Pathway:
Terminated NCT03959033 - Patient Reported Outcome Measures (PROMs) With Trabectedin
Not yet recruiting NCT06414434 - BTX-A51 in Patients With Liposarcoma Phase 1
Withdrawn NCT03880123 - Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma Phase 1
Active, not recruiting NCT02978859 - Sitravatinib in Advanced Liposarcoma and Other Soft Tissue Sarcomas Phase 2
Recruiting NCT02275286 - Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients Phase 1/Phase 2
Completed NCT01426633 - Combination Therapy of Gemcitabine and Trabectedin in L-sarcomas Phase 1
Completed NCT00400569 - Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma Phase 2
Recruiting NCT04028479 - The Registry of Oncology Outcomes Associated With Testing and Treatment
Recruiting NCT04785196 - APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT02571829 - A Phase II Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well/Dedifferentiated Liposarcoma Phase 2
Completed NCT00060944 - A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer Phase 2